Study S002121

Efficacy and Safety of Once-weekly Supaglutide Versus Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Metformin: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04998032
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 620
Start: 2021-10-12
Primary completion: 2023-06-15
Lead sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions: Type2 Diabetes
Interventions: BIOLOGICAL:supaglutide injection+metformin; OTHER:placebo+metformin
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

HbA1c [12 weeks for phase IIb; 24weeks and 52 weeks for phase III]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006975	Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2). Jia W, Nature communications	2026	Randomized trial	PMID 42103705 DOI	cites ClinicalTrials.gov:NCT04998032; registry reference DERIVED:42103705
R0006753	Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes. Lou YR, Clinical pharmacokinetics	2025	Other trial	PMID 39961992 DOI	cites ClinicalTrials.gov:NCT04998032; registry reference DERIVED:39961992
R0009296	Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Treated with Metformin. Wang Q, Clinical pharmacokinetics	2025	Randomized trial	PMID 40991141 DOI	cites ClinicalTrials.gov:NCT04998032; registry reference DERIVED:40991141
R0051200	778-P: Efficacy and Safety of Supaglutide as Add-on to Metformin in Patients with Type 2 Diabetes DILBAR ANWAR, Diabetes	2023	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04998032